{"MedlineCitation": {"@Status": "MEDLINE", "@Owner": "NLM", "@IndexingMethod": "Automated", "PMID": {"@Version": "1", "#text": "36857419"}, "DateCompleted": {"Year": "2023", "Month": "06", "Day": "19"}, "DateRevised": {"Year": "2024", "Month": "01", "Day": "10"}, "Article": {"@PubModel": "Print", "Journal": {"ISSN": {"@IssnType": "Electronic", "#text": "2473-9537"}, "JournalIssue": {"@CitedMedium": "Internet", "Volume": "7", "Issue": "12", "PubDate": {"Year": "2023", "Month": "Jun", "Day": "27"}}, "Title": "Blood advances", "ISOAbbreviation": "Blood Adv"}, "ArticleTitle": "HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.", "Pagination": {"StartPage": "2758", "EndPage": "2771", "MedlinePgn": "2758-2771"}, "ELocationID": {"@EIdType": "doi", "@ValidYN": "Y", "#text": "10.1182/bloodadvances.2022008893"}, "Abstract": {"AbstractText": "Chimeric antigen receptor-associated hemophagocytic lymphohistiocytosis (HLH)-like toxicities (LTs) involving hyperferritinemia, multiorgan dysfunction, coagulopathy, and/or hemophagocytosis are described as occurring in a subset of patients with cytokine release syndrome (CRS). Case series report poor outcomes for those with B-cell acute lymphoblastic leukemia (B-ALL) who develop HLH-LTs, although larger outcomes analyses of children and young adults (CAYAs) with B-ALL who develop these toxicities after the administration of commercially available tisagenlecleucel are not described. Using a multi-institutional database of 185 CAYAs with B-ALL, we conducted a retrospective cohort study including groups that developed HLH-LTs, high-grade (HG) CRS without HLH-LTs, or no to low-grade (NLG) CRS without HLH-LTs. Primary objectives included characterizing the incidence, outcomes, and preinfusion factors associated with HLH-LTs. Among 185 CAYAs infused with tisagenlecleucel, 26 (14.1%) met the criteria for HLH-LTs. One-year overall survival and relapse-free survival were 25.7% and 4.7%, respectively, in those with HLH-LTs compared with 80.1% and 57.6%, respectively, in those without. In multivariable analysis for death, meeting criteria for HLH-LTs carried a hazard ratio of 4.61 (95% confidence interval, 2.41-8.83), controlling for disease burden, age, and sex. Patients who developed HLH-LTs had higher pretisagenlecleucel disease burden, ferritin, and C-reactive protein levels and lower platelet and absolute neutrophil counts than patients with HG- or NLG-CRS without HLH-LTs. Overall, CAYAs with B-ALL who developed HLH-LTs after tisagenlecleucel experienced high rates of relapse and nonrelapse mortality, indicating the urgent need for further investigations into prevention and optimal management of patients who develop HLH-LTs after tisagenlecleucel.", "CopyrightInformation": "\u00a9 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved."}, "AuthorList": {"@CompleteYN": "Y", "Author": [{"@ValidYN": "Y", "LastName": "McNerney", "ForeName": "Kevin O", "Initials": "KO", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-4359-3569"}, "AffiliationInfo": [{"Affiliation": "Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL."}, {"Affiliation": "Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD."}]}, {"@ValidYN": "Y", "LastName": "Si Lim", "ForeName": "Stephanie J", "Initials": "SJ", "AffiliationInfo": {"Affiliation": "Division of Oncology, Department of Pediatrics, John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI."}}, {"@ValidYN": "Y", "LastName": "Ishikawa", "ForeName": "Kyle", "Initials": "K", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-4181-8648"}, "AffiliationInfo": {"Affiliation": "Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI."}}, {"@ValidYN": "Y", "LastName": "Dreyzin", "ForeName": "Alexandra", "Initials": "A", "AffiliationInfo": {"Affiliation": "Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC."}}, {"@ValidYN": "Y", "LastName": "Vatsayan", "ForeName": "Anant", "Initials": "A", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-2993-0490"}, "AffiliationInfo": {"Affiliation": "Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC."}}, {"@ValidYN": "Y", "LastName": "Chen", "ForeName": "John J", "Initials": "JJ", "AffiliationInfo": {"Affiliation": "Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI."}}, {"@ValidYN": "Y", "LastName": "Baggott", "ForeName": "Christina", "Initials": "C", "AffiliationInfo": {"Affiliation": "Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA."}}, {"@ValidYN": "Y", "LastName": "Prabhu", "ForeName": "Snehit", "Initials": "S", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-8589-3087"}, "AffiliationInfo": {"Affiliation": "Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA."}}, {"@ValidYN": "Y", "LastName": "Pacenta", "ForeName": "Holly L", "Initials": "HL", "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, University of Texas Southwestern Medical Center/Children's Health, Dallas, TX."}, {"Affiliation": "Division of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX."}]}, {"@ValidYN": "Y", "LastName": "Philips", "ForeName": "Christine", "Initials": "C", "AffiliationInfo": [{"Affiliation": "Division of Pediatrics, University of Cincinnati, Cincinnati, OH."}, {"Affiliation": "Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH."}]}, {"@ValidYN": "Y", "LastName": "Rossoff", "ForeName": "Jenna", "Initials": "J", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-0471-9883"}, "AffiliationInfo": {"Affiliation": "Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL."}}, {"@ValidYN": "Y", "LastName": "Stefanski", "ForeName": "Heather E", "Initials": "HE", "AffiliationInfo": {"Affiliation": "National Marrow Donor Program/Be the Match, Minneapolis, MN."}}, {"@ValidYN": "Y", "LastName": "Talano", "ForeName": "Julie-An", "Initials": "JA", "AffiliationInfo": {"Affiliation": "Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI."}}, {"@ValidYN": "Y", "LastName": "Moskop", "ForeName": "Amy", "Initials": "A", "AffiliationInfo": {"Affiliation": "Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI."}}, {"@ValidYN": "Y", "LastName": "Verneris", "ForeName": "Michael", "Initials": "M", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-7097-5917"}, "AffiliationInfo": {"Affiliation": "University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO."}}, {"@ValidYN": "Y", "LastName": "Myers", "ForeName": "Doug", "Initials": "D", "AffiliationInfo": {"Affiliation": "Department of Hematology, Oncology and Blood and Marrow Transplantation, Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO."}}, {"@ValidYN": "Y", "LastName": "Karras", "ForeName": "Nicole A", "Initials": "NA", "AffiliationInfo": {"Affiliation": "Department of Pediatrics, City of Hope National Medical Center, Duarte, CA."}}, {"@ValidYN": "Y", "LastName": "Brown", "ForeName": "Patrick", "Initials": "P", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-8653-1069"}, "AffiliationInfo": {"Affiliation": "Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins University School of Medicine, Baltimore, MD."}}, {"@ValidYN": "Y", "LastName": "Bonifant", "ForeName": "Challice L", "Initials": "CL", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-9028-1683"}, "AffiliationInfo": {"Affiliation": "Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins University School of Medicine, Baltimore, MD."}}, {"@ValidYN": "Y", "LastName": "Qayed", "ForeName": "Muna", "Initials": "M", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-7689-343X"}, "AffiliationInfo": {"Affiliation": "Division of Pediatric Hematology/Oncology and Bone Marrow Transplantation, Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA."}}, {"@ValidYN": "Y", "LastName": "Hermiston", "ForeName": "Michelle", "Initials": "M", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-1790-2679"}, "AffiliationInfo": {"Affiliation": "University of California San Francisco Benioff Children's Hospital, San Francisco, CA."}}, {"@ValidYN": "Y", "LastName": "Satwani", "ForeName": "Prakash", "Initials": "P", "AffiliationInfo": {"Affiliation": "Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY."}}, {"@ValidYN": "Y", "LastName": "Krupski", "ForeName": "Christa", "Initials": "C", "AffiliationInfo": [{"Affiliation": "Division of Pediatrics, University of Cincinnati, Cincinnati, OH."}, {"Affiliation": "Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH."}]}, {"@ValidYN": "Y", "LastName": "Keating", "ForeName": "Amy K", "Initials": "AK", "AffiliationInfo": {"Affiliation": "University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO."}}, {"@ValidYN": "Y", "LastName": "Baumeister", "ForeName": "Susanne H C", "Initials": "SHC", "AffiliationInfo": [{"Affiliation": "Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA."}, {"Affiliation": "Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA."}, {"Affiliation": "Department of Pediatrics, Harvard Medical School, Boston, MA."}]}, {"@ValidYN": "Y", "LastName": "Fabrizio", "ForeName": "Vanessa A", "Initials": "VA", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-8405-1141"}, "AffiliationInfo": {"Affiliation": "University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO."}}, {"@ValidYN": "Y", "LastName": "Chinnabhandar", "ForeName": "Vasant", "Initials": "V", "AffiliationInfo": {"Affiliation": "Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN."}}, {"@ValidYN": "Y", "LastName": "Egeler", "ForeName": "Emily", "Initials": "E", "AffiliationInfo": {"Affiliation": "Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA."}}, {"@ValidYN": "Y", "LastName": "Mavroukakis", "ForeName": "Sharon", "Initials": "S", "AffiliationInfo": {"Affiliation": "Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA."}}, {"@ValidYN": "Y", "LastName": "Curran", "ForeName": "Kevin J", "Initials": "KJ", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-3337-9956"}, "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY."}, {"Affiliation": "Department of Pediatrics, Weill Cornell Medical College, Cornell University, New York, NY."}]}, {"@ValidYN": "Y", "LastName": "Mackall", "ForeName": "Crystal L", "Initials": "CL", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-0359-9023"}, "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA."}, {"Affiliation": "Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA."}, {"Affiliation": "Department of Medicine, School of Medicine, Stanford University, Stanford, CA."}]}, {"@ValidYN": "Y", "LastName": "Laetsch", "ForeName": "Theodore W", "Initials": "TW", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-8497-3138"}, "AffiliationInfo": [{"Affiliation": "Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA."}, {"Affiliation": "Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA."}]}, {"@ValidYN": "Y", "LastName": "Schultz", "ForeName": "Liora M", "Initials": "LM", "AffiliationInfo": {"Affiliation": "Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA."}}]}, "Language": "eng", "GrantList": {"@CompleteYN": "Y", "Grant": [{"GrantID": "P30 CA008748", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "U01 FD005978", "Acronym": "FD", "Agency": "FDA HHS", "Country": "United States"}, {"GrantID": "U54 MD007601", "Acronym": "MD", "Agency": "NIMHD NIH HHS", "Country": "United States"}, {"GrantID": "UL1 TR001085", "Acronym": "TR", "Agency": "NCATS NIH HHS", "Country": "United States"}]}, "PublicationTypeList": {"PublicationType": [{"@UI": "D016428", "#text": "Journal Article"}, {"@UI": "D052061", "#text": "Research Support, N.I.H., Extramural"}, {"@UI": "D013486", "#text": "Research Support, U.S. Gov't, Non-P.H.S."}]}}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Blood Adv", "NlmUniqueID": "101698425", "ISSNLinking": "2473-9529"}, "ChemicalList": {"Chemical": [{"RegistryNumber": "Q6C9WHR03O", "NameOfSubstance": {"@UI": "C000626284", "#text": "tisagenlecleucel"}}, {"RegistryNumber": "0", "NameOfSubstance": {"@UI": "D011948", "#text": "Receptors, Antigen, T-Cell"}}, {"RegistryNumber": "0", "NameOfSubstance": {"@UI": "D000076962", "#text": "Receptors, Chimeric Antigen"}}]}, "CitationSubset": "IM", "MeshHeadingList": {"MeshHeading": [{"DescriptorName": {"@UI": "D006801", "@MajorTopicYN": "N", "#text": "Humans"}}, {"DescriptorName": {"@UI": "D002648", "@MajorTopicYN": "N", "#text": "Child"}}, {"DescriptorName": {"@UI": "D055815", "@MajorTopicYN": "N", "#text": "Young Adult"}}, {"DescriptorName": {"@UI": "D051359", "@MajorTopicYN": "Y", "#text": "Lymphohistiocytosis, Hemophagocytic"}, "QualifierName": {"@UI": "Q000209", "@MajorTopicYN": "N", "#text": "etiology"}}, {"DescriptorName": {"@UI": "D012189", "@MajorTopicYN": "N", "#text": "Retrospective Studies"}}, {"DescriptorName": {"@UI": "D011948", "@MajorTopicYN": "N", "#text": "Receptors, Antigen, T-Cell"}}, {"DescriptorName": {"@UI": "D000076962", "@MajorTopicYN": "Y", "#text": "Receptors, Chimeric Antigen"}}, {"DescriptorName": {"@UI": "D015452", "@MajorTopicYN": "Y", "#text": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma"}, "QualifierName": {"@UI": "Q000150", "@MajorTopicYN": "N", "#text": "complications"}}, {"DescriptorName": {"@UI": "D002051", "@MajorTopicYN": "Y", "#text": "Burkitt Lymphoma"}, "QualifierName": {"@UI": "Q000150", "@MajorTopicYN": "N", "#text": "complications"}}, {"DescriptorName": {"@UI": "D002908", "@MajorTopicYN": "N", "#text": "Chronic Disease"}}]}, "CoiStatement": "Conflict-of-interest disclosure: C.L.M. is a coinventor on numerous patents related to chimeric antigen receptor (CAR) therapies; is a cofounder of Lyell Immunopharma, Syncopation Life Sciences, and Link Cell Therapies, which are developing CAR-based therapies; and consults for Lyell, NeoImmune Tech, Apricity, Nektar, Immatics, Ensoma, Mammoth, Glaxo Smith Kline, and Bristol Myers Squibb. J.-A.T. serves on the advisory board for Novartis. V.A.F. has served as a consultant at Adaptimmune. K.J.C. has served on the advisory board for Novartis and Atara Biotherapeutics and has received research funding from Novartis, Atara Biotherapeutics, Cellectis, and Bristol Myers Squibb. C.L.B. has received research funding from Merck, Sharp, and Dohme, Inc., Bristol Myers Squibb, and Kiadis Pharma and has pending patent applications in the field of engineered cellular therapy.\u00a0\u00a0T.W.L. has held consulting or advisory roles for Novartis, Bayer, Cellectis, Aptitude Health, Clinical Education Alliance, Deciphera, Juno Health, Massive Bio, Med Learning Group, Medscape, Physicians\u2019 Education Resource, Y-mAbs Therapeutics, Advanced Microbubbles, AI Therapeutics, Jazz Pharaceuticals, GentiBio, Menarini, and Pyramid Biosciences. L.M.S. has served on the advisory board for Novartis. The remaining authors declare no competing financial interests."}, "PubmedData": {"History": {"PubMedPubDate": [{"@PubStatus": "accepted", "Year": "2023", "Month": "2", "Day": "19"}, {"@PubStatus": "received", "Year": "2022", "Month": "9", "Day": "7"}, {"@PubStatus": "medline", "Year": "2023", "Month": "6", "Day": "19", "Hour": "13", "Minute": "8"}, {"@PubStatus": "pubmed", "Year": "2023", "Month": "3", "Day": "2", "Hour": "6", "Minute": "0"}, {"@PubStatus": "entrez", "Year": "2023", "Month": "3", "Day": "1", "Hour": "14", "Minute": "3"}, {"@PubStatus": "pmc-release", "Year": "2023", "Month": "3", "Day": "5"}]}, "PublicationStatus": "ppublish", "ArticleIdList": {"ArticleId": [{"@IdType": "pubmed", "#text": "36857419"}, {"@IdType": "pmc", "#text": "PMC10275701"}, {"@IdType": "doi", "#text": "10.1182/bloodadvances.2022008893"}, {"@IdType": "pii", "#text": "494746"}]}, "ReferenceList": {"Reference": [{"Citation": "Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N\u00a0Engl J Med. 2018;378(5):439\u2013448.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5996391"}, {"@IdType": "pubmed", "#text": "29385370"}]}}, {"Citation": "Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J\u00a0Clin Oncol. 2015;33(27):2938\u20132948.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4567699"}, {"@IdType": "pubmed", "#text": "26304874"}]}}, {"Citation": "Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N\u00a0Engl J Med. 2014;371(16):1507\u20131517.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4267531"}, {"@IdType": "pubmed", "#text": "25317870"}]}}, {"Citation": "Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119\u2013122.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4119809"}, {"@IdType": "pubmed", "#text": "24667956"}]}}, {"Citation": "Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u2013679.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5448406"}, {"@IdType": "pubmed", "#text": "27076371"}]}}, {"Citation": "Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC6733403"}, {"@IdType": "pubmed", "#text": "28925994"}]}}, {"Citation": "Henter JI, Horne A, Aric\u00f3 M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u2013131.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "16937360"}}}, {"Citation": "Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J\u00a0Clin Oncol. 2020;38(17):1938\u20131950.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7280047"}, {"@IdType": "pubmed", "#text": "32286905"}]}}, {"Citation": "Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T-cells. Blood. 2021;138(24):2469\u20132484.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8832442"}, {"@IdType": "pubmed", "#text": "34525183"}]}}, {"Citation": "Hines MR, Keenan C, Maron Alfaro G, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021;194(4):701\u2013707.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8756350"}, {"@IdType": "pubmed", "#text": "34263927"}]}}, {"Citation": "Ahmed S, Furqan F, Strati P, et al. Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel) J\u00a0Clin Oncol. 2020;38(suppl 15):8057."}, {"Citation": "Priyadarshini S, Harris A, Treisman D, et al. Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: update from the FDA and Vizient databases. Am J Hematol. 2022;97(10):E374\u2013E376.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "35870117"}}}, {"Citation": "Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u2013638.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30592986"}}}, {"Citation": "Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961\u20131968.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC9006295"}, {"@IdType": "pubmed", "#text": "34788386"}]}}, {"Citation": "Schultz LM, Baggott C, Prabhu S, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J\u00a0Clin Oncol. 2022;40(9):945\u2013955.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC9384925"}, {"@IdType": "pubmed", "#text": "34882493"}]}}, {"Citation": "Ravich JW, Huang S, Zhou Y, et al. Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel. Transplant Cell Ther. 2022;28(2):73.e1\u201373.e9.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8816862"}, {"@IdType": "pubmed", "#text": "34875402"}]}}, {"Citation": "Myers RM, Taraseviciute A, Steinberg SM, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J\u00a0Clin Oncol. 2022;40(9):932\u2013944.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8937010"}, {"@IdType": "pubmed", "#text": "34767461"}]}}, {"Citation": "Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis: highly elevated ferritin levels and HLH. Pediatr Blood Cancer. 2008;50(6):1227\u20131235.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "18085676"}}}, {"Citation": "Kadauke S, Myers RM, Li Y, et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J\u00a0Clin Oncol. 2021;39(8):920\u2013930.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8462622"}, {"@IdType": "pubmed", "#text": "33417474"}]}}, {"Citation": "Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735\u2013743.", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "15069016"}}}, {"Citation": "Faramand R, Jain M, Staedtke V, et al. Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res. 2020;26(18):4823\u20134831.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7501265"}, {"@IdType": "pubmed", "#text": "32669372"}]}}, {"Citation": "Burleigh K, Kus A, Long A, et al. Poor clinical outcome in pediatric immunotherapy is mediated by a pre-existing overactive IL-18-IFNy immune phenotype. Blood. 2021;138(suppl 1):168."}, {"Citation": "Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332\u20131343.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8212354"}, {"@IdType": "pubmed", "#text": "32107531"}]}}, {"Citation": "Craver BM, El Alaoui K, Scherber RM, Fleischman AG. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers. 2018;10(4):104.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5923359"}, {"@IdType": "pubmed", "#text": "29614027"}]}}, {"Citation": "Radujkovic A, Kordelas L, Bogdanov R, et al. Interleukin-18 and hematopoietic recovery after allogeneic stem cell transplantation. Cancers. 2020;12(10):2789.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7601738"}, {"@IdType": "pubmed", "#text": "32998441"}]}}, {"Citation": "Rabilloud T, Potier D, Pankaew S, Nozais M, Loosveld M, Payet-Bornet D. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun. 2021;12(1):865.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7870924"}, {"@IdType": "pubmed", "#text": "33558546"}]}}, {"Citation": "Bailey SR, Vatsa S, Larson RC, et al. Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 2022;3(2):136\u2013153.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC9414118"}, {"@IdType": "pubmed", "#text": "35015685"}]}}, {"Citation": "McNerney KO, DiNofia AM, Teachey DT, Grupp SA, Maude SL. Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy. Blood Cancer Discov. 2022;3(2):90\u201394.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC9245357"}, {"@IdType": "pubmed", "#text": "35015687"}]}}, {"Citation": "Park JH, Sauter CS, Palomba ML, et al. A\u00a0phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma. Blood. 2021;138(suppl 1):96."}, {"Citation": "Strati P, Ahmed S, Kebriaei P, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123\u20133127.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7362369"}, {"@IdType": "pubmed", "#text": "32645136"}]}}, {"Citation": "Pulsipher MA, Han X, Maude SL, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022;3(1):66\u201381.", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC9924295"}, {"@IdType": "pubmed", "#text": "35019853"}]}}]}}}
{"MedlineCitation": {"@Status": "MEDLINE", "@Owner": "NLM", "@IndexingMethod": "Automated", "PMID": {"@Version": "1", "#text": "36108252"}, "DateCompleted": {"Year": "2023", "Month": "01", "Day": "09"}, "DateRevised": {"Year": "2024", "Month": "01", "Day": "11"}, "Article": {"@PubModel": "Print-Electronic", "Journal": {"ISSN": {"@IssnType": "Electronic", "#text": "1527-7755"}, "JournalIssue": {"@CitedMedium": "Internet", "Volume": "41", "Issue": "2", "PubDate": {"Year": "2023", "Month": "Jan", "Day": "10"}}, "Title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "ISOAbbreviation": "J Clin Oncol"}, "ArticleTitle": "Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.", "Pagination": {"StartPage": "354", "EndPage": "363", "MedlinePgn": "354-363"}, "ELocationID": {"@EIdType": "doi", "@ValidYN": "Y", "#text": "https://doi.org/10.1200/JCO.22.01076"}, "Abstract": {"AbstractText": [{"@Label": "PURPOSE", "#text": "Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively, whereas use in the real-world setting showed nonresponse and relapse rates of 15% and 37%. Outcome analyses describing fate after post-CAR nonresponse and relapse remain limited. Here, we aim to establish survival outcomes after nonresponse and both CD19+ and CD19- relapses and explore treatment variables associated with inferior survival."}, {"@Label": "METHODS", "#text": "We conducted a retrospective multi-institutional study of 80 children and young adults with B-cell acute lymphoblastic leukemia experiencing nonresponse (n = 23) or relapse (n = 57) after tisagenlecleucel. We analyze associations between baseline characteristics and these outcomes and establish survival rates and salvage approaches."}, {"@Label": "RESULTS", "i": "P", "#text": "The overall survival (OS) at 12 months was 19% across nonresponders (n = 23; 95% CI, 7 to 50). Ninety-five percent of patients with nonresponse had high preinfusion disease burden. Among 156 morphologic responders, the cumulative incidence of relapse was 37% (95% CI, 30 to 47) at 12 months (CD19+; 21% [15 to 29], CD19-; 16% [11 to 24], median follow-up; 380 days). Across 57 patients experiencing relapse, the OS was 52% (95% CI, 38 to 71) at 12 months after time of relapse. Notably, CD19- relapse was associated with significantly decreased OS as compared with patients who relapsed with conserved CD19 expression (CD19- 12-month OS; 30% [14 to 66], CD19+ 12-month OS; 68% [49 to 92],  = .0068). Inotuzumab, CAR reinfusion, and chemotherapy were used as postrelapse salvage therapy with greatest frequency, yet high variability in treatment sequencing and responses limits efficacy analysis across salvage approaches."}, {"@Label": "CONCLUSION", "#text": "We describe poor survival across patients experiencing nonresponse to tisagenlecleucel. In the post-tisagenlecleucel relapse setting, patients can be salvaged; however, CD19- relapse is distinctly associated with decreased survival outcomes."}]}, "AuthorList": {"@CompleteYN": "Y", "Author": [{"@ValidYN": "Y", "LastName": "Schultz", "ForeName": "Liora M", "Initials": "LM", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-9512-7597"}, "AffiliationInfo": {"Affiliation": "Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA."}}, {"@ValidYN": "Y", "LastName": "Eaton", "ForeName": "Anne", "Initials": "A", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-5900-9745"}, "AffiliationInfo": {"Affiliation": "Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN."}}, {"@ValidYN": "Y", "LastName": "Baggott", "ForeName": "Christina", "Initials": "C", "AffiliationInfo": {"Affiliation": "Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA."}}, {"@ValidYN": "Y", "LastName": "Rossoff", "ForeName": "Jenna", "Initials": "J", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-0471-9883"}, "AffiliationInfo": {"Affiliation": "Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL."}}, {"@ValidYN": "Y", "LastName": "Prabhu", "ForeName": "Snehit", "Initials": "S", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-8589-3087"}, "AffiliationInfo": {"Affiliation": "Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA."}}, {"@ValidYN": "Y", "LastName": "Keating", "ForeName": "Amy K", "Initials": "AK", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-4187-8456"}, "AffiliationInfo": {"Affiliation": "University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO."}}, {"@ValidYN": "Y", "LastName": "Krupski", "ForeName": "Christa", "Initials": "C", "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, University of Cincinnati, Cincinnati, OH."}, {"Affiliation": "Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH."}]}, {"@ValidYN": "Y", "LastName": "Pacenta", "ForeName": "Holly", "Initials": "H", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-4913-5208"}, "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX."}, {"Affiliation": "Division of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX."}]}, {"@ValidYN": "Y", "LastName": "Philips", "ForeName": "Christine L", "Initials": "CL", "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, University of Cincinnati, Cincinnati, OH."}, {"Affiliation": "Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH."}]}, {"@ValidYN": "Y", "LastName": "Talano", "ForeName": "Julie-An", "Initials": "JA", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-2645-0854"}, "AffiliationInfo": {"Affiliation": "Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI."}}, {"@ValidYN": "Y", "LastName": "Moskop", "ForeName": "Amy", "Initials": "A", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-5110-004X"}, "AffiliationInfo": {"Affiliation": "Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI."}}, {"@ValidYN": "Y", "LastName": "Baumeister", "ForeName": "Susanne H C", "Initials": "SHC", "AffiliationInfo": {"Affiliation": "Pediatric Hematology-Oncology, Harvard Medical School, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA."}}, {"@ValidYN": "Y", "LastName": "Myers", "ForeName": "Gary Douglas", "Initials": "GD", "AffiliationInfo": {"Affiliation": "Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO."}}, {"@ValidYN": "Y", "LastName": "Karras", "ForeName": "Nicole A", "Initials": "NA", "AffiliationInfo": {"Affiliation": "Department of Pediatrics, City of Hope National Medical Center, Duarte, CA."}}, {"@ValidYN": "Y", "LastName": "Brown", "ForeName": "Patrick A", "Initials": "PA", "AffiliationInfo": {"Affiliation": "Department of Oncology, Sidney Kimmel Cancer Center at John Hopkins School of Medicine, Baltimore, MD."}}, {"@ValidYN": "Y", "LastName": "Qayed", "ForeName": "Muna", "Initials": "M", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-7689-343X"}, "AffiliationInfo": {"Affiliation": "Emory University and Children's Healthcare of Atlanta, Druid Hills, GA."}}, {"@ValidYN": "Y", "LastName": "Hermiston", "ForeName": "Michelle", "Initials": "M", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-1790-2679"}, "AffiliationInfo": {"Affiliation": "University of California San Francisco Benioff Children's Hospital, San Francisco, CA."}}, {"@ValidYN": "Y", "LastName": "Satwani", "ForeName": "Prakash", "Initials": "P", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-3867-9066"}, "AffiliationInfo": {"Affiliation": "Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY."}}, {"@ValidYN": "Y", "LastName": "Wilcox", "ForeName": "Rachel", "Initials": "R", "AffiliationInfo": {"Affiliation": "Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO."}}, {"@ValidYN": "Y", "LastName": "Rabik", "ForeName": "Cara A", "Initials": "CA", "AffiliationInfo": {"Affiliation": "Division of Hematologic Malignancies I, Center for Drug Evaluation and Research (CDER), FDA."}}, {"@ValidYN": "Y", "LastName": "Fabrizio", "ForeName": "Vanessa A", "Initials": "VA", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-8405-1141"}, "AffiliationInfo": [{"Affiliation": "University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO."}, {"Affiliation": "Department of Pediatrics, Memorial Sloan Kettering Cancer Center."}, {"Affiliation": "Department of Pediatrics, Weill Cornell Medical College."}]}, {"@ValidYN": "Y", "LastName": "Chinnabhandar", "ForeName": "Vasant", "Initials": "V", "AffiliationInfo": {"Affiliation": "Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN."}}, {"@ValidYN": "Y", "LastName": "Kunicki", "ForeName": "Michael", "Initials": "M", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-6630-6289"}, "AffiliationInfo": {"Affiliation": "Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA."}}, {"@ValidYN": "Y", "LastName": "Mavroukakis", "ForeName": "Sharon", "Initials": "S", "AffiliationInfo": {"Affiliation": "Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA."}}, {"@ValidYN": "Y", "LastName": "Egeler", "ForeName": "Emily", "Initials": "E", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-5173-0335"}, "AffiliationInfo": {"Affiliation": "Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA."}}, {"@ValidYN": "Y", "LastName": "Li", "ForeName": "Yimei", "Initials": "Y", "Identifier": {"@Source": "ORCID", "#text": "0000-0001-9067-6992"}, "AffiliationInfo": [{"Affiliation": "Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA."}, {"Affiliation": "Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA."}, {"Affiliation": "Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA."}]}, {"@ValidYN": "Y", "LastName": "Mackall", "ForeName": "Crystal L", "Initials": "CL", "Identifier": {"@Source": "ORCID", "#text": "0000-0003-0359-9023"}, "AffiliationInfo": [{"Affiliation": "Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA."}, {"Affiliation": "Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, CA."}, {"Affiliation": "Division of Blood and Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, CA."}]}, {"@ValidYN": "Y", "LastName": "Curran", "ForeName": "Kevin J", "Initials": "KJ", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-3337-9956"}, "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, Memorial Sloan Kettering Cancer Center."}, {"Affiliation": "Department of Pediatrics, Weill Cornell Medical College."}]}, {"@ValidYN": "Y", "LastName": "Verneris", "ForeName": "Michael R", "Initials": "MR", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-7097-5917"}, "AffiliationInfo": {"Affiliation": "University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO."}}, {"@ValidYN": "Y", "LastName": "Laetsch", "ForeName": "Theodore W", "Initials": "TW", "Identifier": {"@Source": "ORCID", "#text": "0000-0002-8497-3138"}, "AffiliationInfo": [{"Affiliation": "Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX."}, {"Affiliation": "Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA."}, {"Affiliation": "Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA."}, {"Affiliation": "Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA."}]}, {"@ValidYN": "Y", "LastName": "Stefanski", "ForeName": "Heather", "Initials": "H", "AffiliationInfo": {"Affiliation": "Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN."}}]}, "Language": "eng", "GrantList": {"@CompleteYN": "Y", "Grant": [{"GrantID": "P30 CA008748", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "UL1 TR001085", "Acronym": "TR", "Agency": "NCATS NIH HHS", "Country": "United States"}, {"GrantID": "UL1 TR003142", "Acronym": "TR", "Agency": "NCATS NIH HHS", "Country": "United States"}]}, "PublicationTypeList": {"PublicationType": [{"@UI": "D016428", "#text": "Journal Article"}, {"@UI": "D052061", "#text": "Research Support, N.I.H., Extramural"}, {"@UI": "D013485", "#text": "Research Support, Non-U.S. Gov't"}]}, "ArticleDate": {"@DateType": "Electronic", "Year": "2022", "Month": "09", "Day": "15"}}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Clin Oncol", "NlmUniqueID": "8309333", "ISSNLinking": "0732-183X"}, "ChemicalList": {"Chemical": [{"RegistryNumber": "Q6C9WHR03O", "NameOfSubstance": {"@UI": "C000626284", "#text": "tisagenlecleucel"}}, {"RegistryNumber": "0", "NameOfSubstance": {"@UI": "D011948", "#text": "Receptors, Antigen, T-Cell"}}, {"RegistryNumber": "0", "NameOfSubstance": {"@UI": "D018941", "#text": "Antigens, CD19"}}]}, "CitationSubset": "IM", "CommentsCorrectionsList": {"CommentsCorrections": {"@RefType": "CommentIn", "RefSource": "Transl Pediatr. 2023 Dec 26;12(12):2095-2098. doi: 10.21037/tp-23-421.", "PMID": {"@Version": "1", "#text": "38197106"}}}, "MeshHeadingList": {"MeshHeading": [{"DescriptorName": {"@UI": "D006801", "@MajorTopicYN": "N", "#text": "Humans"}}, {"DescriptorName": {"@UI": "D002648", "@MajorTopicYN": "N", "#text": "Child"}}, {"DescriptorName": {"@UI": "D055815", "@MajorTopicYN": "N", "#text": "Young Adult"}}, {"DescriptorName": {"@UI": "D000293", "@MajorTopicYN": "N", "#text": "Adolescent"}}, {"DescriptorName": {"@UI": "D012189", "@MajorTopicYN": "N", "#text": "Retrospective Studies"}}, {"DescriptorName": {"@UI": "D011948", "@MajorTopicYN": "Y", "#text": "Receptors, Antigen, T-Cell"}, "QualifierName": {"@UI": "Q000627", "@MajorTopicYN": "N", "#text": "therapeutic use"}}, {"DescriptorName": {"@UI": "D015452", "@MajorTopicYN": "Y", "#text": "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma"}, "QualifierName": {"@UI": "Q000188", "@MajorTopicYN": "N", "#text": "drug therapy"}}, {"DescriptorName": {"@UI": "D016219", "@MajorTopicYN": "N", "#text": "Immunotherapy, Adoptive"}}, {"DescriptorName": {"@UI": "D012008", "@MajorTopicYN": "N", "#text": "Recurrence"}}, {"DescriptorName": {"@UI": "D018941", "@MajorTopicYN": "N", "#text": "Antigens, CD19"}}, {"DescriptorName": {"@UI": "D002908", "@MajorTopicYN": "N", "#text": "Chronic Disease"}}]}, "CoiStatement": {"b": ["Heather Stefanski", "Honoraria:"], "#text": ".  Novartis. No other potential conflicts of interest were reported."}}, "PubmedData": {"History": {"PubMedPubDate": [{"@PubStatus": "pubmed", "Year": "2022", "Month": "9", "Day": "16", "Hour": "6", "Minute": "0"}, {"@PubStatus": "medline", "Year": "2023", "Month": "1", "Day": "10", "Hour": "6", "Minute": "0"}, {"@PubStatus": "entrez", "Year": "2022", "Month": "9", "Day": "15", "Hour": "16", "Minute": "2"}, {"@PubStatus": "pmc-release", "Year": "2024", "Month": "1", "Day": "10"}]}, "PublicationStatus": "ppublish", "ArticleIdList": {"ArticleId": [{"@IdType": "pubmed", "#text": "36108252"}, {"@IdType": "pmc", "#text": "PMC9839307"}, {"@IdType": "doi", "#text": "10.1200/JCO.22.01076"}]}, "ReferenceList": {"Reference": [{"Citation": "Maude SL, Laetsch TW, Buechner J, et al. : Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439-448, 2018", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5996391"}, {"@IdType": "pubmed", "#text": "29385370"}]}}, {"Citation": "Schultz LM, Baggott C, Prabhu S, et al. : Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: A pediatric real-world chimeric antigen receptor Consortium report. J Clin Oncol 40:945-955, 2021", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC9384925"}, {"@IdType": "pubmed", "#text": "34882493"}]}}, {"Citation": "Curran KJ, Pegram HJ, Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med 14:405-415, 2012", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4697438"}, {"@IdType": "pubmed", "#text": "22262649"}]}}, {"Citation": "Gardner RA, Finney O, Annesley C, et al. : Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322-3331, 2017", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC5482103"}, {"@IdType": "pubmed", "#text": "28408462"}]}}, {"Citation": "Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. : T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 385:517-528, 2015", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7065359"}, {"@IdType": "pubmed", "#text": "25319501"}]}}, {"Citation": "Pasquini MC, Hu ZH, Curran K, et al. : Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 4:5414-5424, 2020", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7656920"}, {"@IdType": "pubmed", "#text": "33147337"}]}}, {"Citation": "Majzner RG, Mackall CL: Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8:1219-1226, 2018", "ArticleIdList": {"ArticleId": {"@IdType": "pubmed", "#text": "30135176"}}}, {"Citation": "Sotillo E, Barrett DM, Black KL, et al. : Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282-1295, 2015", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC4670800"}, {"@IdType": "pubmed", "#text": "26516065"}]}}, {"Citation": "O'Brien MM, Ji L, Shah NN, et al. : Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group protocol AALL1621. J Clin Oncol 40:956-967, 2022", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8937013"}, {"@IdType": "pubmed", "#text": "35007127"}]}}, {"Citation": "Shah NN, Highfill SL, Shalabi H, et al. : CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: Updated results from a phase I anti-CD22 CAR T-cell trial. J Clin Oncol 38:1938-1950, 2020", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC7280047"}, {"@IdType": "pubmed", "#text": "32286905"}]}}, {"Citation": "Spiegel JY, Patel S, Muffly L, et al. : CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial. Nat Med 27:1419-1431, 2021", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8363505"}, {"@IdType": "pubmed", "#text": "34312556"}]}}, {"Citation": "Cordoba S, Onuoha S, Thomas S, et al. : CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: A phase 1 trial. Nat Med 27:1797-1805, 2021", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8516648"}, {"@IdType": "pubmed", "#text": "34642489"}]}}, {"Citation": "Gardner RA, Annesley C, Wilson A, et al. : Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity. J Clin Oncol 38, 2020. (15 suppl; abstr 3035)"}, {"Citation": "Myers RM, Taraseviciute A, Steinberg SM, et al. : Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol 40:932-944, 2022", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8937010"}, {"@IdType": "pubmed", "#text": "34767461"}]}}, {"Citation": "Kadauke S, Myers RM, Li Y, et al. : Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial. J Clin Oncol 39:920-930, 2021", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8462622"}, {"@IdType": "pubmed", "#text": "33417474"}]}}, {"Citation": "Fabrizio VA, Phillips CL, Lane A, et al. : Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A pediatric real world CAR Consortium report. Blood Adv 6:600-610, 2022", "ArticleIdList": {"ArticleId": [{"@IdType": "pmc", "#text": "PMC8791593"}, {"@IdType": "pubmed", "#text": "34794180"}]}}]}}}
